• Kravchun N. A. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv
  • Khyzhnyak O. O. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv



diabetes mellitus, treatment, Glymepyride, GliclazideMR


Results of the hypoglycemic therapeutic efficiency of Gliclazide and Glimepiride in patients with type 2 diabetes mellitus are represented in the open prospective study. Daily dose of GliclazideMR was 90 mg, and Glimepiride — 4 mg. It is evident that third-generation sulfonylurea — Glimepiride has more protective cardiovascular effects because it significantly decreases microalbumiurea. Moreover, it significantly improves postprandial and basal glycemia, and the HDLP cholesterol level in patients with 5-year DM2 history. As an anti-diabetic drug Glimepiride has some advantages with regard to a high risk of microvascular complications when the disease is in progress.


Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy [Text] / A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. — 2008. — Vol. 31, № 12.

Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes [Text] / S. Schwartz, V. Fonseca, B. Berner [et al.] // Diabetes Care. — 2006. — Vol. 29, № 4.

Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ [Текст]: рук. для практикующих врачей / И. И. Дедов [и др.]; под общ. ред. И. И. Дедова, Г. А. Мельниченко. — М.: Литтерра, 2006. — Т. 12. — С. 41–49.

Müller G. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes [Text] / G. Müller, K. // Geisen. Horm. Metabol. Res. — 1996. — Vol. 28 (9). — P. 469–87.

Rosskamp R. Clinical profile of the novel sulphonylurea glimepiride [Text] / R. Rosskamp, K. Wernicke-Panten, E. Draeger // Diabetes. Res. Clin. Pract. — 1996. — Vol. 31. — S33–42.

Балаболкин М. И. Лечение сахарного диабета и его осложнений [Текст]: учеб. пособие / М. И. Балаболкин, Е. М. Клебанова, В. М. реминская. — М.: ОАО «Изд-во Медицина», 2005. — С. 151–256.

Influence of oral sulfonylurea agents on hepatic glucose uptake [Text] / R. Kawamori, T. Morishima, M. [et al.] // Diabetes Res. Clin. Pract. — 1995. — Vol. 28. — S 109–13.

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus [Text] / D. Y. Xu, S. P. Zhao, Q. X. Huang [et al.] // Diabetes Res. Clin. Pract. — 2009. — Vol. 30.

Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents [Text] / S. T. de Dios, K. V. Frontanilla, J. Nigro, [et al.] // J. Diabetes Compl. — 2007. — Vol. 21 (2). — P. 108–17.

Holstein A. Glimeperide induces a lower incidence of severe hypoglycemia in patients with type 2 diabetes than glibenclamide [Text] / A. Holstein, A. Plashke, E-H. Egbert // Hypoglicemia from research to practice. Asisi, Italy. — 2001. — № 26–29. — Abstracts 41.

Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience [Text] / W. B. Kannel, R. B. D’Agostino, P.W. Wilson [et al.] // Am. Heart. J. — 1990. — Vol. 120. — P. 672–676.

Classification of hyperlipidemias and hyoperlipoproteinemias [Text] / J. L. Beaumot, L. A. Carlson, G. R. Cooper [et al.] // Bull. WHO. — 1970. — Vol. 43. — P. 891.

Климов А. Н. Обмен липидов и липопротеидов и его нарушения [Текст] / А. Н. Климов, Н. Г. Никуличева. — СПб.: Питер Ком, 1999. — 512 с.




How to Cite

Kravchun, N. A., & Khyzhnyak, O. (2010). COMPARATIVE ANALYSIS OF GLIMEPIRIDE AND GLICLAZIDEMR USE IN TYPE 2 DIABETES MELLITUS TREATMENT. Problems of Endocrine Pathology, 31(1), 5-11.




Most read articles by the same author(s)

1 2 3 4 5 > >>